8-K: Theriva Biologics Reports Full-Year 2023 Results and Provides Clinical Program Update

Theriva Biologics announced its full-year 2023 financial results and provided an update on its clinical programs, highlighting the progress of its VIRAGE trial and a cash runway into the first quarter of 2025.

Summary

• Theriva Biologics reported its financial results for the year ended December 31, 2023, and provided an update on its clinical programs.
• The company's cash balance was $23.2 million as of December 31, 2023, which is expected to fund operations into the first quarter of 2025.
• General and administrative expenses decreased by 28% to $7.1 million in 2023, compared to $9.9 million in 2022.
• Research and development expenses increased by 22% to $14.3 million in 2023, up from $11.7 million in 2022, primarily due to the VIRAGE trial.
• The company's net loss for 2023 was $18.3 million, compared to a net loss of $19.7 million in 2022.
• The VIRAGE Phase 2b trial for VCN-01 in pancreatic cancer is on track to complete enrollment in the first half of 2024.
• The Independent Data Monitoring Committee (IDMC) recommended the continuation of the VIRAGE trial without any changes to the protocol.
• The Phase 1 trial of intravitreal VCN-01 in pediatric retinoblastoma has completed patient treatment and will complete follow-up in the first half of 2024.
• The Phase 1b/2a trial of SYN-004 in allogeneic HCT recipients is on track to complete enrollment into the second cohort in Q2 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture with positive clinical trial progress and cost control, but also significant losses and a high cash burn rate. The going concern note from the auditor is a concern.

Positives

• The company has a solid cash position of $23.2 million, providing a runway into the first quarter of 2025.
• The VIRAGE trial is progressing as planned with no safety concerns raised by the IDMC.
• General and administrative expenses have decreased significantly, indicating improved cost management.
• The company is actively pursuing licensing discussions for its SYN-020 asset.
• The company has strengthened its research collaboration with Sant Joan de Du-Barcelona Childrens Hospital.

Negatives

• The company experienced a net loss of $18.3 million for the year ended December 31, 2023.
• Research and development expenses increased by 22%, primarily due to the VIRAGE trial, which may indicate higher future costs.
• Cash and cash equivalents decreased from $41.8 million to $23.2 million year-over-year.
• The company's independent auditor included an explanatory paragraph related to the company's ability to continue as a going concern.

Risks

• The company's ability to reach clinical milestones as anticipated is subject to various factors.
• The company's product candidates may not demonstrate safety and effectiveness.
• The company may face challenges in obtaining regulatory approval for its product candidates.
• The company's products may not be accepted in the marketplace.
• The company's ability to maintain license agreements and its patent estate is crucial.
• The company's ability to remain well financed is essential for continued operations.

Future Outlook

The company expects research and development expenses to increase as it continues enrollment in its VIRAGE Phase 2 clinical trial, expands GMP manufacturing activities for VCN-01, and supports other preclinical and discovery initiatives. The company anticipates achieving several important milestones this year with continued advancement of its clinical programs.

Management Comments

• With continued advancement of our clinical programs, we have the opportunity to achieve several important milestones this year, said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
• Our clinical data has demonstrated that repeated systemic dosing of VCN-01 is feasible from a safety perspective, and will now focus on determining whether the repeated-dose regimen of VCN-01 may lead to improved clinical outcomes for patients with PDAC and other solid cancers.

Industry Context

Theriva Biologics is operating in the competitive biotechnology sector, focusing on developing novel therapies for cancer and related diseases. The company's focus on oncolytic adenoviruses and microbiome modulation aligns with current trends in cancer research and treatment. The progress of the VIRAGE trial is a key indicator of the company's potential in the pancreatic cancer space.

Comparison to Industry Standards

• Theriva's cash runway into Q1 2025 is a positive sign, but the burn rate is high and will need to be monitored against other similar stage biotech companies.
• The 22% increase in R&D spending is typical for a company advancing multiple clinical programs, but the company will need to demonstrate value for money.
• The decrease in G&A expenses is a positive sign of cost control, which is important for early-stage biotech companies.
• The company's focus on oncolytic viruses is in line with the industry's interest in novel cancer therapies, but the company will need to demonstrate efficacy and safety in its clinical trials.
• Companies such as Oncolytics Biotech and Replimune are also developing oncolytic virus therapies, and Theriva will need to differentiate itself in this competitive landscape.

Stakeholder Impact

• Shareholders will be interested in the company's cash runway and clinical trial progress.
• Employees will be impacted by the company's financial performance and future growth.
• Patients will benefit from the development of new therapies for cancer and related diseases.
• Suppliers and creditors will be impacted by the company's financial stability.

Next Steps

• The company will continue enrollment in the VIRAGE Phase 2b trial for pancreatic cancer.
• The company will complete patient follow-up in the Phase 1 trial of intravitreal VCN-01 in pediatric retinoblastoma in H1 2024.
• The company will complete enrollment into the second cohort of the SYN-004 trial in Q2 2024.
• The company will continue to pursue licensing discussions for its SYN-020 asset.
• The company will expand GMP manufacturing activities for VCN-01.

Key Dates

Keywords

Theriva Biologics, VCN-01, SYN-004, SYN-020, Pancreatic Ductal Adenocarcinoma, Retinoblastoma, Clinical Trial, Oncolytic Adenovirus, Ribaxamase, Hematopoietic Cell Transplant